Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial

Yosuke Horita; Yasuhide Yamada; Ken Kato; Yoshinori Hirashima; Kouhei Akiyoshi; Kengo Nagashima; Takako Nakajima; Tetsuya Hamaguchi; Yasuhiro Shimada

首页> 外文期刊>International Journal of Clinical Oncology >Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial

【24h】

Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial

机译：二线FOLFIRI联合贝伐单抗治疗转移性结直肠癌的II期临床试验：AVASIRI试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

FOLFIRI is a standard chemotherapy regimen for the treatment of metastatic colorectal cancer. Although some studies have shown its efficacy in combination with bevacizumab as first-line chemotherapy, there are no data to support FOLFIRI plus bevacizumab as second-line chemotherapy in patients with this form of cancer. The aim of this study was to evaluate the efficacy and safety of FOLFIRI and bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.

机译：FOLFIRI是用于治疗转移性结直肠癌的标准化疗方案。尽管一些研究表明它与贝伐单抗联合作为一线化疗的疗效，但尚无数据支持FOLFIRI加贝伐单抗作为这种癌症患者的二线化疗。这项研究的目的是评估FOLFIRI和贝伐单抗作为转移性结直肠癌患者二线化疗的疗效和安全性。

著录项

来源
《International Journal of Clinical Oncology》 |2012年第6期|p.604-609|共6页
作者
Yosuke Horita; Yasuhide Yamada; Ken Kato; Yoshinori Hirashima; Kouhei Akiyoshi; Kengo Nagashima; Takako Nakajima; Tetsuya Hamaguchi; Yasuhiro Shimada;
展开▼
作者单位

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Department of Medical Oncology, Faculty of Medicine, Oita University, Oita, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Laboratory of Biostatistics, Faculty of Pharmaceutical Sciences, Josai University, Saitama, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
FOLFIRI; Bevacizumab; Second-line; Colorectal cancer;

机译：FOLFIRI;贝伐单抗;二线;大肠癌;

相似文献

外文文献
中文文献
专利

1. Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. [J] . Yosuke Horita, Yasuhide Yamada, Ken Kato, International journal of clinical oncology . 2012,第6期

机译：二线FOLFIRI联合贝伐单抗治疗转移性结直肠癌的II期临床试验：AVASIRI试验。
2. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab [J] . Masahito Kotaka, Ruihua Xu, Kei Muro, Chinese journal of cancer . 2016,第1期

机译：亚洲XELIRI项目（AXEPT）的研究方案：一项针对转移性结直肠癌的二线化疗的跨国，非劣效，非劣效性III期临床试验，比较了有或没有贝伐单抗与有或没有贝伐单抗的FOLFIRI的疗效和安全性
3. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab [J] . Masahito Kotaka, Ruihua Xu, Kei Muro, Cancer Communications . 2016,第1期

机译：亚洲XELIRI项目（AXEPT）的研究方案：一项针对转移性结直肠癌的二线化疗的跨国，非劣效，非劣效性III期临床试验，比较了有或没有贝伐单抗与有或没有贝伐单抗的FOLFIRI的疗效和安全性
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
6. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational randomized non-inferiority phase III trial of second-line chemotherapy for metastatic colorectal cancer comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab [O] . Masahito Kotaka, Ruihua Xu, Kei Muro, 2016

机译：亚洲XELIRI ProjecT（AXEPT）的研究方案：一项针对转移性结直肠癌的二线化疗的跨国非劣效非劣效性三期临床试验比较了XELIRI联合或不联合贝伐单抗与FOLFIRI联合或不联合贝伐单抗的疗效和安全性
7. Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT) [O] . T.W. Kim, Y.S. Park, K. Muro, 2017

机译：转移性结肠直肠癌二线化疗的随机，非劣等，III期试验（MCRC），比较Xeliri + Bevacizumab的疗效和安全性与Folfiri + Bevacizumab（Axept）

Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial

摘要

著录项

相似文献

相关主题

期刊订阅